IB2004/004096

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07K16/42 A61K39/395 A61K35/12 A61P35/00 C12N5/08 According to International Patent Classification ($\underline{\text{IPC}}$) or to both national classification and IPC B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) CO7K C12N A61K A61P IPC 7 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the International search (name of data base and, where practical, search terms used) EPO-Internal, BIOSIS, EMBASE, CHEM ABS Data, WPI Data, PAJ, Sequence Search C. DOCUMENTS CONSIDERED TO BE RELEVANT Relevant to daim No. Citation of document, with indication, where appropriate, of the relevant passages 1-15 "Murine monoclonal R. BARAL ET AL.: Y anti-idiotypic antibody as a surrogate antigen for human Her-2/Neu." INTERNATIONAL JOURNAL OF CANCER. vol. 92, 2001, pages 88-95, XP002285279 cited in the application abstract Patent family members are listed in annex. Further documents are listed in the continuation of box C. X Special categories of cited documents: *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the *A* document defining the general state of the art which is not considered to be of particular relevance invention "X" document of particular relevance; the claimed Invention cannot be considered novel or cannot be considered to "E" earlier document but published on or after the international filing date Involve an inventive step when the document is taken alone "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such docucitation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or ments, such combination being obvious to a person skilled other means 'P' document published prior to the international filing date but later than the priority date claimed *&* document member of the same patent family Date of mailing of the international search report Date of the actual completion of the international search 24/02/2005 11 February 2005 Authorized officer Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentiaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016 Nooij, F

.(Conunu	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	Relevant to claim No.	
ategory °	Citation of document, with indication, where appropriate, of the relevant passages		
1	P. MAITI ET AL.: "Development of a single chain Fv from a human anti-ID monoclonal antibody that mimics the GD2 antigen: A vaccine candidate for cancer immunotherapy." PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 43, March 2002 (2002-03), page 970, XP002285280 USA * abstract #4805 *	1-15	
Y	WO 95/10303 A (OKLAHOMA MEDICAL RESEARCH FOUNDATION ET AL.) 20 April 1995 (1995-04-20) page 24, line 1 - page 25, line 17 claims 13,14	1-15	
Υ .	D. LEUNG ET AL.: "A human and a mouse anti-idiotypic antibody specific for human T14+ anti-DNA antibodies reconstructed by phage display." GENE, vol. 255, 2000, pages 373-380, XP004217652 cited in the application abstract	1-15	
Y	L. DURRANT ET AL.: "Human anti-idiotypic antibodies can be good immunogens as they target Fc receptors on antigen-presenting cells allowing" INTERNATIONAL JOURNAL OF CANCER, vol. 92, no. 3, 1 May 2001 (2001-05-01), pages 414-420, XP002285281 abstract page 415, left-hand column, line 4 - line 29	1-15	
Y	M. SALEH ET AL.: "Generation of a human anti-idiotypic antibody that mimics the GD2 antigen." THE JOURNAL OF IMMUNOLOGY, vol. 151, no. 6, 15 September 1993 (1993-09-15), pages 3390-3398, XP002091381 BALTIMORE, MD, USA abstract page 3390, right-hand column, line 12 - line 26 page 3396, right-hand column, line 12 - line 28	1-15	

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT							
Category °	the state of the selection of the select	Relevant to claim No.					
Y	A. SAHA ET AL.: "Murine dendritic cells pulsed with an anti-idiotype antibody induce antigen-specific protective antitumor immunity." CANCER RESEARCH, vol. 63, 1 June 2003 (2003-06-01), pages 2844-2854, XP002285282 USA cited in the application abstract	9-11, 13-15					
Y	US 5 637 677 A (GREENE ET AL) 10 June 1997 (1997-06-10) column 23 claims 20,21	7					
P,X	M. COELHO ET AL.: "Isolation and characterisation of a human anti-idiotypic scFv used as a surrogate tumour antigen to elicit an anti-HER-2/neu humoral response in mice." BRITISH JOURNAL OF CANCER, vol. 90, no. 10, 17 May 2004 (2004-05-17), pages 2032-2041, XP002317270 GB the whole document	1-8					

PCT/IB2004/004096

Box No	Nucleotide and/or amino acid sequence(s) (Continuation of item 1.b of the first sheet)
1. V	fith regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed vention, the international search was carried out on the basis of:
a	type of material X a sequence listing table(s) related to the sequence listing
b	format of material X in written format X in computer readable form
c	time of filing/furnishing X contained in the international application as filed X filed together with the International application in computer readable form furnished subsequently to this Authority for the purpose of search
2. [In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3. A	dditional comments:

Box II Observations where certain claims were found unsearchable (Continuation of Item 2 of first sheet)					
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:					
1. X Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:					
Although claims 13-15 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the com_ound/composition.					
Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:					
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).					
Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)					
This International Searching Authority found multiple Inventions in this international application, as follows:					
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.					
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.					
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:					
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; It is covered by claims Nos.:					
Remark on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.					

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 9510303	A	20-04-1995	US	5560911 A	01-10-1996
			ΑT	176758 T	15-03-1999
			ΑU	688806 B2	19-03-1998
l			ΑU	7973694 A	04-05-1995
			CA	2172819 A1	20-04-1995
			DE	69416601 D1	25-03-1999
1			DE	69416601 T2	22-07-1999
			DK	728016 T3	20-09-1999
			EP	0728016 A1	28-08-1996
			ES	2131218 T3	16-07-1999
ĺ			WO	9510303 A1	20-04-1995
			US	5728812 A	17-03-1998
US 5637677	Α	10-06-1997	US	2003144479 A1	31-07-2003
			US	6372884 B1	16-04-2002
			AT	140233 T	15-07-1996
			DE	68926813 D1	14-08-1996
			DE	68926813 T2	17-07-1997
<u></u>			EP	0370090 A1	30-05-1990
			JP	2504284 T	06-12-1990
			WO	8910939 A1	16-11-1989
1			ΑT	229974 T	15-01-2003
			CA	2091258 A1	15-03-1992
			DE	69133181 D1	30-01-2003
			DE	69133181 T2	30-04-2003
			EP	1310557 A1	14-05-2003
Ī			EP	0551440 A1	21-07-1993
ì			JP	6504271 T	19-05-1994
			WO	9204914 A1	02-04-1992